Top

European Archives of Oto-Rhino-Laryngology

Published in:

Open Access 08-08-2023 | Rhinology

Nomograms containing body dose parameters for predicting survival in patients with nasopharyngeal carcinoma

Authors: Jianyun Jiang, Ruiping Zhai, Fangfang Kong, Chengrun Du, Hongmei Ying

Published in: European Archives of Oto-Rhino-Laryngology | Issue 1/2024

Abstract

Purpose

To assess the impact of body dose on survival outcomes in nasopharyngeal carcinoma (NPC) patients and to create novel nomograms incorporating body dose parameters for predicting survival.

Methods

594 of non-metastasis NPC patients (training group, 396; validation group, 198) received intensity-modulated radiation therapy at our institution from January 2012 to December 2016. Patient characteristics, body dose parameters in dose–volume histogram (DVH) and hematology profiles were collected for predicting overall survival (OS) and progression-free survival (PFS). Nomograms for OS and PFS were developed using the selected predictors. Each nomogram was evaluated based on its C-index and calibration curve.

Results

Body dose-based risk score for OS (RS_OS), N stage, age, and induction chemotherapy were independent predictors for OS, with a C-index of 0.784 (95% CI 0.749–0.819) in the training group and 0.763 (95% CI 0.715–0.810) in the validation group for the nomogram. As for PFS, the most important predictors were the body dose-based risk score for PFS (RS_PFS)_, N stage, and induction chemotherapy. C-index of PFS nomogram was 0.706 (95% CI 0.681–0.720) in the training group and 0.691 (95% CI 0.662–0.711) in the validation group. The two models outperformed the TNM staging system in predicting outcomes.

Conclusions

Body dose coverage is a useful predictor of prognosis in clinical routine patients. The novel nomograms integrating body dose parameters can precisely predict OS and PFS in NPC patients.

Available only for authorised users

Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J (2019) Nasopharyngeal carcinoma. Lancet (London, England) 394(10192):64–80. https://doi.org/10.1016/S0140-6736(19)30956-0CrossRefPubMed

Sun X-S, Liu S-L, Luo M-J, Li X-Y, Chen Q-Y, Guo S-S, Wen Y-F, Liu L-T, Xie H-J, Tang Q-N et al (2019) The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012. Int J Radiat Oncol Biol Physics 105(3):581–590. https://doi.org/10.1016/j.ijrobp.2019.06.2549CrossRef

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ et al (2018) NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Canc Netw 16(5):479–490. https://doi.org/10.6004/jnccn.2018.0026CrossRefPubMed

Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, Deng X, Huang S, Lin C, Lu T (2014) Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol J Eur Soc Therap Radiol Oncol 110(3):398–403. https://doi.org/10.1016/j.radonc.2013.10.020CrossRef

Cao C-n, Luo J-w, Gao L, Yi J-l, Huang X-d, Wang K, Zhang S-p, Qu Y, Li S-y, Xiao J-p et al (2015) Update report of T4 classification nasopharyngeal carcinoma after intensity-modulated radiotherapy: an analysis of survival and treatment toxicities. Oral Oncol 51(2):190–194. https://doi.org/10.1016/j.oraloncology.2014.11.009CrossRefPubMed

Lee AWM, Ng WT, Chan JYW, Corry J, Mäkitie A, Mendenhall WM, Rinaldo A, Rodrigo JP, Saba NF, Strojan P et al (2019) Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev 79:101890. https://doi.org/10.1016/j.ctrv.2019.101890CrossRefPubMed

Ng W-T, Wong ECY, Cheung AKW, Chow JCH, Poon DMC, Lai JWY, Chiang C-L, Choi HCW, Chau T-C, Lee VHF et al (2019) Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT-A study by the HKNPCSG. Head Neck 41(10):3661–3669. https://doi.org/10.1002/hed.25892CrossRefPubMed

Leong YH, Soon YY, Lee KM, Wong LC, Tham IWK, Ho FCH (2018) Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy: a meta-analysis. Head Neck 40(3):622–631. https://doi.org/10.1002/hed.24993CrossRefPubMed

Lee AW, Ng WT, Pan JJ, Chiang C-L, Poh SS, Choi HC, Ahn YC, AlHussain H, Corry J, Grau C et al (2019) International guideline on dose prioritization and acceptance criteria in radiation therapy planning for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Physics 105(3):567–580. https://doi.org/10.1016/j.ijrobp.2019.06.2540CrossRef

10.

Wang J, Qing G, Ou X, Hu W, Hu C, Zhang Z (2019) The impact of target dosimetry on patients’ locoregional recurrence in nasopharyngeal carcinoma: A propensity score-matched analysis. Radiother Oncol J Eur Soc Therap Radiol Oncol 141:67–71. https://doi.org/10.1016/j.radonc.2019.09.001CrossRef

11.

Ng WT, Lee MCH, Chang ATY, Chan OSH, Chan LLK, Cheung FY, Hung WM, Chan CCC, Lee AWM (2014) The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT. Oral Oncol 50(5):506–512. https://doi.org/10.1016/j.oraloncology.2014.01.017CrossRefPubMed

12.

Xue F, Hu C, He X (2018) Impact of minimum point dose on local control and toxicity in T3–4 nasopharyngeal carcinoma treated with intensity-modulated radiation therapy plus chemotherapy. Jpn J Clin Oncol 48(3):265–271. https://doi.org/10.1093/jjco/hyx183CrossRefPubMed

13.

Ng WT, Lee MCH, Hung WM, Choi CW, Lee KC, Chan OSH, Lee AWM (2011) Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Physics 79(2):420–428. https://doi.org/10.1016/j.ijrobp.2009.11.024CrossRef

14.

Wang L, Guo Y, Xu J, Chen Z, Jiang X, Zhang L, Huang S, He X, Zhang Y (2017) Clinical analysis of recurrence patterns in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. Ann Otol Rhinol Laryngol 126(12):789–797. https://doi.org/10.1177/0003489417734229CrossRefPubMed

15.

Corbeau A, Kuipers SC, de Boer SM, Horeweg N, Hoogeman MS, Godart J, Nout RA (2021) Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review. Radiother Oncol J Eur Soc Therap Radiol Oncol 164:128–137. https://doi.org/10.1016/j.radonc.2021.09.009CrossRef

16.

Xu C-J, van der Schaaf A, Schilstra C, Langendijk JA (2012) van’t Veld AA: Impact of statistical learning methods on the predictive power of multivariate normal tissue complication probability models. Int J Radiat Oncol Biol Physics 82(4):e677–e684. https://doi.org/10.1016/j.ijrobp.2011.09.036CrossRef

17.

Tang X-R, Li Y-Q, Liang S-B, Jiang W, Liu F, Ge W-X, Tang L-L, Mao Y-P, He Q-M, Yang X-J et al (2018) Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol 19(3):382–393. https://doi.org/10.1016/S1470-2045(18)30080-9CrossRefPubMed

18.

Mijnheer BJ, Battermann JJ, Wambersie A (1987) What degree of accuracy is required and can be achieved in photon and neutron therapy? Radiother Oncol J Eur Soc Therap Radiol Oncol 8(3):237–252CrossRef

19.

Wittkämper FW, Mijnheer BJ, van Kleffens HJ: Dose intercomparison at the radiotherapy centers in The Netherlands. 2. Accuracy of locally applied computer planning systems for external photon beams. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology 1988, 11(4):405–414

20.

Hodapp N: [The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)]. Strahlenther Onkol 2012, 188(1):97–99.https://doi.org/10.1007/s00066-011-0015-x

21.

Das IJ, Andersen A, Chen ZJ, Dimofte A, Glatstein E, Hoisak J, Huang L, Langer MP, Lee C, Pacella M et al (2017) State of dose prescription and compliance to international standard (ICRU-83) in intensity modulated radiation therapy among academic institutions. Pract Radiat Oncol 7(2):e145–e155. https://doi.org/10.1016/j.prro.2016.11.003CrossRefPubMed

22.

Liao W, He J, Liu Z, Tian M, Yang J, Han J, Xiao J (2021) A novel dosimetric metrics-based risk model to predict local recurrence in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. Radiat Oncol 16(1):186. https://doi.org/10.1186/s13014-021-01911-5CrossRefPubMedPubMedCentral

23.

Riesco A (1970) Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25(1):135–140CrossRefPubMed

24.

Liu L-T, Chen Q-Y, Tang L-Q, Guo S-S, Guo L, Mo H-Y, Chen M-Y, Zhao C, Guo X, Qian C-N et al (2018) The prognostic value of treatment-related lymphopenia in nasopharyngeal carcinoma patients. Cancer Res Treat 50(1):19–29. https://doi.org/10.4143/crt.2016.595CrossRefPubMed

25.

Du C, Ni M, Jiang J, Kong F, Zhai R, Lv Y, Hu C, Ying H (2022) Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis. Eur Arch Otorhinolaryngol 279(8):3947–3956. https://doi.org/10.1007/s00405-021-07192-8CrossRefPubMedPubMedCentral

26.

Chua MLK, Tan SH, Kusumawidjaja G, Shwe MTT, Cheah SL, Fong KW, Soong YL, Wee JTS, Tan TWK (2016) Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: a pooled analysis of two randomised controlled trials. Eur J Cancer (Oxford, England : 1990) 67:119–129. https://doi.org/10.1016/j.ejca.2016.08.006CrossRef

27.

Yuan X, Feng H, Huang H, Li J, Wu S, Yuan Y, Cui L, Lin D, Chen Z, Lu W et al (2023) Systemic immune-inflammation index during treatment predicts prognosis and guides clinical treatment in patients with nasopharyngeal carcinoma. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-022-04506-zCrossRefPubMedPubMedCentral

28.

Peng R-R, Liang Z-G, Chen K-H, Li L, Qu S, Zhu X-D (2021) Nomogram based on lactate dehydrogenase-to-albumin ratio (LAR) and platelet-to-lymphocyte ratio (PLR) for predicting survival in nasopharyngeal carcinoma. J Inflamm Res 14:4019–4033. https://doi.org/10.2147/JIR.S322475CrossRefPubMedPubMedCentral

29.

Lu A, Li H, Zheng Y, Tang M, Li J, Wu H, Zhong W, Gao J, Ou N, Cai Y (2017) Prognostic significance of neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio, and platelet to lymphocyte ratio in patients with nasopharyngeal carcinoma. BioMed Res Int. https://doi.org/10.1155/2017/3047802CrossRefPubMedPubMedCentral

30.

Zhao R, Liang Z, Chen K, Zhu X (2022) Nomogram based on inflammatory biomarkers and nutritional indicators for predicting overall survival in locoregionally advanced nasopharyngeal carcinoma. J Inflamm Res 15:2971–2981. https://doi.org/10.2147/JIR.S366299CrossRefPubMedPubMedCentral

31.

Kenny PW, Montanari CA (2013) Inflation of correlation in the pursuit of drug-likeness. J Computer-aided Mol Des. https://doi.org/10.1007/s10822-012-9631-5CrossRef

32.

Tang L-Q, Li C-F, Li J, Chen W-H, Chen Q-Y, Yuan L-X, Lai X-P, He Y, Xu Y-X-X, Hu D-P et al (2016) Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv291CrossRefPubMedPubMedCentral

33.

Wan X-b, Wei L, Li H, Dong M, Lin Q, Ma X-k, Huang P-y, Wen J-y, Li X, Chen J et al (2013) High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. Eur J Cancer (Oxford, England : 1990) 49(10):2356–2364. https://doi.org/10.1016/j.ejca.2013.03.008CrossRef

34.

Yang H, Wang K, Liang Z, Guo S, Zhang P, Xu Y, Zhou H (2020) Prognostic role of pre-treatment serum albumin in patients with nasopharyngeal carcinoma: a meta-analysis and systematic review. Clin Otolaryngol 45(2):167–176. https://doi.org/10.1111/coa.13454CrossRefPubMed

35.

Zhang L-L, Xu F, Song D, Huang M-Y, Huang Y-S, Deng Q-L, Li Y-Y, Shao J-Y (2020) Development of a nomogram model for treatment of nonmetastatic nasopharyngeal carcinoma. JAMA Netw Open 3(12):e2029882. https://doi.org/10.1001/jamanetworkopen.2020.29882CrossRefPubMedPubMedCentral

36.

Joseph N, McWilliam A, Kennedy J, Haslett K, Mahil J, Gavarraju A, Mistry H, Van Herk M, Faivre-Finn C, Choudhury A (2019) Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy. Radiother Oncol J Eur Soc Therap Radiol Oncol 135:115–119. https://doi.org/10.1016/j.radonc.2019.03.008CrossRef

37.

Xu C, Jin J-Y, Zhang M, Liu A, Wang J, Mohan R, Kong FS, Lin SH (2020) The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother Oncol J Eur Soc Therap Radiol Oncol 146:180–186. https://doi.org/10.1016/j.radonc.2020.02.015CrossRef

38.

Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T et al (2009) Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114(3):589–595. https://doi.org/10.1182/blood-2009-02-206870CrossRefPubMedPubMedCentral

39.

Grossman SA, Ellsworth S, Campian J, Wild AT, Herman JM, Laheru D, Brock M, Balmanoukian A, Ye X (2015) Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Canc Netw 13(10):1225–1231CrossRefPubMedPubMedCentral

40.

Cho O, Oh Y-T, Chun M, Noh OK, Hoe J-S, Kim H (2016) Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer. Head Neck 38(Suppl 1):E1061–E1067. https://doi.org/10.1002/hed.24158CrossRefPubMed

41.

Venkatesulu B, Giridhar P, Pujari L, Chou B, Lee JH, Block AM, Upadhyay R, Welsh JS, Harkenrider MM, Krishnan S et al (2022) Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): a systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy. Radiother Oncol J Eur Soc Therap Radiol Oncol 177:81–94. https://doi.org/10.1016/j.radonc.2022.10.019CrossRef

42.

Chua DTT, Ma J, Sham JST, Mai H-Q, Choy DTK, Hong M-H, Lu T-X, Min H-Q (2005) Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 23(6):1118–1124CrossRefPubMed

Title: Nomograms containing body dose parameters for predicting survival in patients with nasopharyngeal carcinoma
Authors: Jianyun Jiang
Ruiping Zhai
Fangfang Kong
Chengrun Du
Hongmei Ying
Publication date: 08-08-2023
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Oto-Rhino-Laryngology / Issue 1/2024
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-023-08173-9

2024 ASCO Annual Meeting

Springer Medicine

Nomograms containing body dose parameters for predicting survival in patients with nasopharyngeal carcinoma

Abstract

Purpose

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

The impact of cochlear implantation on quality of life and psychological status in single-sided deafness or asymmetric hearing loss with tinnitus and influencing factors of implantation intention: a preliminary study

Long term results of glass ionomer ossiculoplasty

Instrumental assessment of dynamic postural stability in patients with unilateral vestibular hypofunction during straight, curved, and blindfolded gait

Otosclerosis online: a critical analysis of quality, reliability, readability and content of otosclerosis information

Effectiveness and rapidity on olfatory fuction recovery in CRS patients treated with Dupilumab: a real life prospective controlled study

Olfactory training with four and eight odors: comparison with clinical testing and olfactory bulb volumetrics